Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | RAD52 | P43351 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TTR | P02766 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL842750 | 0.86 | TLR7 (0.38) | CYP1A2MEN1PKMKMT2APOLB | |
| SCHEMBL14345376 | 0.86 | ATM (0.39) | NUDT1CYP1A2MEN1PKMKMT2A | |
| SCHEMBL204050 | 0.84 | KMT2A (0.41) | MEN1PKMKMT2APOLBKDM4E | |
| SCHEMBL19643692 | 0.83 | MEN1 (0.39) | CYP1A2MEN1PKMKMT2AKDM4E | |
| SCHEMBL19643695 | 0.83 | MEN1 (0.39) | CYP1A2MEN1PKMKMT2AKDM4E | |
| SCHEMBL12665011 | 0.81 | POLB (0.44) | MEN1PKMKMT2APOLBRAD52 | |
| SCHEMBL8726008 | 0.81 | CYP1A2 (0.46) | CYP1A2MEN1PKMKMT2APOLB | |
| SCHEMBL204017 | 0.80 | MEN1 (0.48) | MEN1PKMKMT2AGAARAB9A | |
| SCHEMBL4313344 | 0.80 | MAPT (0.40) | NUDT1CYP1A2MEN1PKMKMT2A | |
| SCHEMBL30361640 | 0.80 | MAPT (0.40) | NUDT1CYP1A2MEN1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250222117-A1 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | PURDUE RESEARCH FOUNDATION | 2025-07-10 | — | — | US | disclosed |
| US-20240390505-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR REJUVENATION OF CAR T-CELLS | PURDUE RESEARCH FOUNDATION | 2024-11-28 | — | — | US | disclosed |
| CN-118871104-A | Compounds, compositions, and methods of use comprising raltitrexed or 5-MTHF linked to a therapeutic agent | 普渡研究基金会 | 2024-10-29 | — | — | CN | disclosed |
| CN-118139627-A | Conjugates, compositions and methods for rejuvenating CAR T cells | 普渡研究基金会 | 2024-06-04 | — | — | CN | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | PURDUE RESEARCH FOUNDATION | 2023-08-10 | — | — | US | disclosed |
| EP-4178574-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | Purdue Research Foundation (US) | 2023-05-17 | — | — | EP | disclosed |
| CN-115916342-A | Compounds, compositions and methods for treating fibrotic diseases and cancer | 普渡研究基金会 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022147576-A1 | METHODS FOR ENHANCEMENT OF ENGINEERED CELL THERAPIES IN CANCER TREATMENT | PURDUE RESEARCH FOUNDATION (US) | 2022-07-07 | — | — | WO | disclosed |
| US-8735421-B2 | Imidazoquinolinyl sulfonamides | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-05-27 | — | — | US | disclosed |
| US-20090062272-A1 | IMIDAZOQUINOLINYL SULFONAMIDES | 3M INNOVATIVE PROPERTIES COMPANY | 2009-03-05 | — | — | US | disclosed |
| EP-1699788-A2 | IMIDAZOQUINOLINYL, IMIDAZOPYRIDINYL AND IMIDAZONAPHTHYRIDINYL SULFONAMIDES | 3M Innovative Properties Company (US) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005066169-A2 | IMIDAZOQUINOLINYL, IMIDAZOPYRIDINYL, AND IMIDAZONAPHTHYRIDINYL SULFONAMIDES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230248835-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF FIBROTIC DISEASES AND CANCER | TLR9, TLR8, TLR7 | NUDT1 209/4885CYP1A2 4130/4885MEN1 3475/4885 |
| US-20090062272-A1 | IMIDAZOQUINOLINYL SULFONAMIDES | IL2, EIF2AK2, IFNG | NUDT1 1301/4885CYP1A2 2326/4885MEN1 4334/4885 |
| US-20250222117-A1 | COMPOUND COMPRISING RALTITREXED OR 5-MTHF LINKED TO A THERAPEUTIC AGENT, COMPOSITION, AND METHOD OF USE | MTHFD1, MTHFD2, DHFR | NUDT1 33/4885CYP1A2 1555/4885MEN1 2492/4885 |
| US-20240390505-A1 | CONJUGATES, COMPOSITIONS, AND METHODS FOR REJUVENATION OF CAR T-CELLS | CD47, ICOS, PBK | NUDT1 3678/4885CYP1A2 4640/4885MEN1 1724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.